Matches in SemOpenAlex for { <https://semopenalex.org/work/W2072433522> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2072433522 endingPage "e16" @default.
- W2072433522 startingPage "e15" @default.
- W2072433522 abstract "Treatment for Type 1 retinopathy of prematurity (ROP) includes laser and, more recently, intravitreal injection of bevacizumab. This study uses ROPtool, a photoanalyzer, to objectively measure changes in retinal vascular dilation and tortuosity (plus disease) following intravitreal bevacizumab. Fundus images from 6 newborns treated with intravitreal bevacizumab for ROP were analyzed using ROPtool to assess for changes in tortuosity, dilation and a calculation of overall plus disease. Measurements were obtained at baseline (n = 6), 1 week (n = 6), and 2 weeks (n = 1) after treatment. Average vessel tortuosity decreased by 49%, dilation decreased by 9% and overall plus disease decreased by 17% in the first week after treatment with bevacizumab. One week later, the average vessel tortuosity decreased by another 20%, dilation decreased by 1%, and overall plus disease decreased by 14%. Few studies have shown objective changes in ROP after treatment with laser but no previous studies have shown similar objective findings after treatment with bevacizumab. This study demonstrates a larger decrease in tortuosity at 1 week post-bevacizumab compared to a previous study of post-laser patients analyzed by Computer Assisted Image Analysis Software (that study found only a 2% decrease in tortuosity and 20% decrease in dilation at 1 week). Objective measurements of plus disease show greater changes in tortuosity 1 week after treatment with bevacizumab compared to a previous study of post-laser changes. Understanding the expected pattern of change over time in retinal vascular dilation and tortuosity following bevacizumab guides clinicans’ expectations for ROP regression following this new treatment." @default.
- W2072433522 created "2016-06-24" @default.
- W2072433522 creator A5026703697 @default.
- W2072433522 creator A5035606118 @default.
- W2072433522 creator A5041633089 @default.
- W2072433522 creator A5068651869 @default.
- W2072433522 creator A5091447908 @default.
- W2072433522 date "2013-02-01" @default.
- W2072433522 modified "2023-10-18" @default.
- W2072433522 title "Computer-assisted quantification of plus disease after treatment of retinopathy of prematurity with intravitreal bevacizumab" @default.
- W2072433522 doi "https://doi.org/10.1016/j.jaapos.2012.12.055" @default.
- W2072433522 hasPublicationYear "2013" @default.
- W2072433522 type Work @default.
- W2072433522 sameAs 2072433522 @default.
- W2072433522 citedByCount "0" @default.
- W2072433522 crossrefType "journal-article" @default.
- W2072433522 hasAuthorship W2072433522A5026703697 @default.
- W2072433522 hasAuthorship W2072433522A5035606118 @default.
- W2072433522 hasAuthorship W2072433522A5041633089 @default.
- W2072433522 hasAuthorship W2072433522A5068651869 @default.
- W2072433522 hasAuthorship W2072433522A5091447908 @default.
- W2072433522 hasConcept C118487528 @default.
- W2072433522 hasConcept C127413603 @default.
- W2072433522 hasConcept C141071460 @default.
- W2072433522 hasConcept C185250623 @default.
- W2072433522 hasConcept C187320778 @default.
- W2072433522 hasConcept C2776391266 @default.
- W2072433522 hasConcept C2776694085 @default.
- W2072433522 hasConcept C2777802072 @default.
- W2072433522 hasConcept C2778376644 @default.
- W2072433522 hasConcept C2779234561 @default.
- W2072433522 hasConcept C2779918416 @default.
- W2072433522 hasConcept C2780827179 @default.
- W2072433522 hasConcept C54355233 @default.
- W2072433522 hasConcept C6648577 @default.
- W2072433522 hasConcept C71924100 @default.
- W2072433522 hasConcept C86803240 @default.
- W2072433522 hasConceptScore W2072433522C118487528 @default.
- W2072433522 hasConceptScore W2072433522C127413603 @default.
- W2072433522 hasConceptScore W2072433522C141071460 @default.
- W2072433522 hasConceptScore W2072433522C185250623 @default.
- W2072433522 hasConceptScore W2072433522C187320778 @default.
- W2072433522 hasConceptScore W2072433522C2776391266 @default.
- W2072433522 hasConceptScore W2072433522C2776694085 @default.
- W2072433522 hasConceptScore W2072433522C2777802072 @default.
- W2072433522 hasConceptScore W2072433522C2778376644 @default.
- W2072433522 hasConceptScore W2072433522C2779234561 @default.
- W2072433522 hasConceptScore W2072433522C2779918416 @default.
- W2072433522 hasConceptScore W2072433522C2780827179 @default.
- W2072433522 hasConceptScore W2072433522C54355233 @default.
- W2072433522 hasConceptScore W2072433522C6648577 @default.
- W2072433522 hasConceptScore W2072433522C71924100 @default.
- W2072433522 hasConceptScore W2072433522C86803240 @default.
- W2072433522 hasIssue "1" @default.
- W2072433522 hasLocation W20724335221 @default.
- W2072433522 hasOpenAccess W2072433522 @default.
- W2072433522 hasPrimaryLocation W20724335221 @default.
- W2072433522 hasRelatedWork W1987205358 @default.
- W2072433522 hasRelatedWork W1991223903 @default.
- W2072433522 hasRelatedWork W2033204288 @default.
- W2072433522 hasRelatedWork W2058971889 @default.
- W2072433522 hasRelatedWork W2077022902 @default.
- W2072433522 hasRelatedWork W2294551244 @default.
- W2072433522 hasRelatedWork W2563437364 @default.
- W2072433522 hasRelatedWork W2797390928 @default.
- W2072433522 hasRelatedWork W3029407746 @default.
- W2072433522 hasRelatedWork W4300689660 @default.
- W2072433522 hasVolume "17" @default.
- W2072433522 isParatext "false" @default.
- W2072433522 isRetracted "false" @default.
- W2072433522 magId "2072433522" @default.
- W2072433522 workType "article" @default.